MCWgreen

Alvarez headshot May 2018Principle Investigator: Dr. Rita V. Alvarez

Disease: Pediatric delirium

Research Description: Altered cognition and consciousness defines delirium. Delirium is a common syndrome in critically ill children, with up to 66% of children in the pediatric intensive care unit (ICU) developing delirium. Delirium leads to increased length of mechanical ventilation, length of ICU stay, mortality and healthcare costs. Currently, there is no approved drug therapy for pediatric delirium. The proposed research will test quetiapine, an FDA approved atypical antipsychotic, in children diagnosed with delirium in the pediatric ICU. The research team will conduct a prospective double-blind, randomized controlled clinical trial to determine if quetiapine is safe and effective in decreasing the duration of pediatric delirium in critically ill children. If successful, quetiapine could be used off label for the treatment of pediatric delirium.

CWR Funding Role: Participating funder

CWR Funding Partner: Goldman Philanthropic Partnerships

CWR Funding Start Date: May 2018

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please email susan@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Sunday the 16th. Copyright 2018 Cures Within Reach.